Page de couverture de JACC Deep Dive

JACC Deep Dive

JACC Deep Dive

Auteur(s): American College of Cardiology
Écouter gratuitement

À propos de cet audio

JACC Deep Dive explores the methodology, interpretation, and impact of key studies published in JACC.American College of Cardiology Foundation. All rights reserved. Hygiène et mode de vie sain Troubles et maladies
Épisodes
  • Percutaneous Mechanical Aspiration: A New Frontier in Endocarditis Care | JACC Deep Dive
    Sep 15 2025

    In this episode of JACC Deep Dive, Editor-in-Chief Dr. Harlan Krumholz explores groundbreaking findings from the CLEAR-IE registry—the largest study to date on percutaneous mechanical aspiration (PMA) for right-sided infective endocarditis. He discusses the procedure’s feasibility, outcomes, and its role alongside surgery, offering insights into how PMA may reshape treatment options for high-risk patients.

    Voir plus Voir moins
    7 min
  • Understanding Angina Symptom Trajectories After Invasive vs. Conservative Treatment | JACC Deep Dive
    Sep 8 2025

    In this JACC Deep Dive, Dr. Harlan Krumholz highlights a study by Ikemura et al. that used data from the ISCHEMIA trial to model how angina symptoms evolve over three years in patients with stable coronary disease treated either invasively or conservatively. The study identified six distinct symptom trajectories, showing that while most patients improved over time, those undergoing revascularization were more likely to experience rapid and complete symptom relief. However, the benefit was not uniform—patients with frequent baseline angina saw the greatest improvement, and some had persistent symptoms regardless of treatment. These findings underscore the importance of personalized, shared decision-making based on a patient's likely symptom trajectory rather than a binary treatment choice.

    Voir plus Voir moins
    8 min
  • Tirzepatide in HFpEF and Obesity: Consistent Benefits Regardless of Diabetes Status | JACC Deep Dive
    Sep 3 2025

    In this JACC Deep Dive, Dr. Harlan Krumholz discusses a pre-specified analysis from the SUMMIT trial, which evaluated the effects of tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, both with and without type 2 diabetes. The study found that tirzepatide significantly improved symptoms, function, and reduced heart failure events, with similar benefits regardless of diabetes status, though weight loss was slightly less in those with diabetes. Importantly, cardiac structural improvements (LV mass and pericardial fat regression) were also similar across both groups, suggesting benefits beyond weight loss alone. The trial's strengths included its integrated design and imaging substudy, though limitations such as modest imaging power and baseline group differences were noted. Clinically, the results support using tirzepatide in HFpEF patients with obesity, regardless of diabetes status, as the benefits remain robust.

    Voir plus Voir moins
    12 min
Pas encore de commentaire